Published Date: 31-Jul-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Non-Steroidal Anti-inflammatory Drugs Market size is expected to reach $25.5 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.
The Topical segment is showcasing a CAGR of 6.1% during (2022 - 2028). The rising demand for topical medications and the widespread accessibility of topical NSAID medicines are anticipated to drive growth throughout the forecast period. For instance, IBSA Pharma Inc.'s Flector (diclofenac epolamine-Topical system) is prescribed for pain brought on by sprains and strains.
The Retail Pharmacy segment acquired maximum revenue share in the Global Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel in 2021 thereby, achieving a market value of $11.8 billion by 2028. The significant market share of retail pharmacies could be ascribed to elements like the rise in NSAID over-the-counter medicine accessibility worldwide and the amount of NSAID prescriptions for pain management. For example, the store-brand Aleve in the United States, OTC Naproxen Sodium Tablets USP, was re-released in August 2021 by Dr. Reddy's Laboratories Ltd.
The Migraine segment is showcasing a CAGR of 6.4% during (2022 - 2028). Due to the high incidence of migraines and the availability of effective treatment options. For example, the sole treatment for migraine attacks that the U.S. FDA has licenced is Advil migraine (Ibuprofen Capsule), produced by GSK plc. Additionally, over-the-counter non-steroidal anti-inflammatory medicine use is growing, which is fueling the segment's expansion over the forecast period.
The North America market dominated the Global Non-steroidal Anti-inflammatory Drugs Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8.8 billion by 2028.The Europe market is exhibiting a CAGR of 5.3% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 6.2% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.
By Route of Administration
By Distribution Channel
By Disease Indication
Unique Offerings from KBV Research